Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
IPO
Biotech
Why US biotech Axiom is starting its IPO journey in Hong Kong
The move follows a phase 1 data drop on Axiom's lead stem cell therapy in the treatment of two fatal newborn neurological diseases.
Marissa Russo
Jul 21, 2026 7:02am
Scribe aims for $96M IPO to fund lipid-lowering genetic meds
Jul 20, 2026 9:48am
Geopolitics ‘chills’ British biotech IPO plans, despite VC boost
Jul 20, 2026 7:45am
Latigo preps IPO to fund non-opioid rival to Vertex’s Journax
Jul 19, 2026 2:07pm
BlossomHill eyes IPO to grow taller in crowded cancer fields
Jul 17, 2026 12:08pm
Vogenx joins the IPO queue to fund phase 2-stage metabolic drug
Jul 16, 2026 5:19am
